Advertisement

THE SEARCH FOR PATHOLOGICALLY VALID IMAGING BIOMARKERS: AD PATHOLOGY COMES NOT ALONE

      Before we have shown that cognitive phenotype in cases with amyotrophic lateral sclerosis was driven by the distribution of TDP-43 in non-motor cortial areas, with some contribution from Alzheimer's disease pathology as quantified by the ABC score. This made us think now in the opposite direction. What would be the contribution of non-AD pathologies, including TDP-43 and alpaha-synnuclein, to the pattern of brain atrophy in cases from the AD spectrum, including two predilection sites of AD, i.e. cholinergic basal forebrain and hippocampus?
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'